|
Senior Researcher
University of Cape Town (UCT), South Africa
Email: mchengalroyen@gmail.com
VALIDATE Role:
Network Associate
Research Keywords:
Tuberculosis, Drug Discovery, CRISPRi Technology, BCG Oral Vaccination
Biography:
My research started in antimycobacterial drug discovery, the molecular mechanisms underlying mycobacterial cofactor biosynthesis and the mismatch DNA repair pathway. This work aimed to identify novel drug targets and compounds for the treatment of tuberculosis, to elucidate the role of cofactors in bacterial physiology and pathogenesis and to investigate DNA repair in the development of drug resistance. Recently, I’ve also developed an interest in the factors that influence BCG vaccination.
Key Publications:
- Chengalroyen M.D., Beukes G.M., Gordhan B.G., Streicher E.M., Churchyard G., Hafner R., Warren R., Otwombe K., Martinson N. and Kana B.D., (2016). Detection and quantification of differentially culturable tubercle bacteria in sputum from tuberculosis patients, American Journal of Respiratory and Critical Care Medicine, DOI:10.1164/rccm.201604-0769OC
- Chengalroyen M.D., (2023). Current Perspectives and Challenges of MAIT Cell-Directed Therapy for Tuberculosis Infection. MDPI Pathogens, doi: 10.3390/pathogens12111343
- Bukula L., Chengalroyen M.D., Omollo C., Moseki M.R., (2024). Factors influencing the efficacy of Bacille Calmette-Guerin (BCG) vaccine. The Microbe, https://doi.org/10.1016/j.microb.2024.100230
- Moseki M.R., Chengalroyen M.D., (2025). Rethinking BCG vaccine delivery for enhanced efficacy: Are two distinct routes of BCG administration better than one? hLife, https://doi.org/10.1016/j.hlife.2024.12.002
|
